NASDAQ:ALLK Allakos (ALLK) Stock Price, News & Analysis $0.69 +0.02 (+2.99%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Allakos Stock (NASDAQ:ALLK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Allakos alerts:Sign Up Key Stats Today's Range$0.67▼$0.7350-Day Range$0.54▼$0.9252-Week Range$0.54▼$3.41Volume253,340 shsAverage Volume816,272 shsMarket Capitalization$61.10 millionP/E RatioN/ADividend YieldN/APrice Target$1.67Consensus RatingHold Company OverviewAllakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.Read More… Who are Nvidia’s New Silent Partners? (Ad)Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Huang consistently has his company ahead of the curve when it comes to artificial intelligence. Nvidia’s added $2 trillion in market cap in 2024.I call these Nvidia’s “Silent Partners.” Allakos Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks82nd Percentile Overall ScoreALLK MarketRank™: Allakos scored higher than 82% of companies evaluated by MarketBeat, and ranked 198th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingAllakos has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageAllakos has only been the subject of 2 research reports in the past 90 days.Read more about Allakos' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Allakos are expected to grow in the coming year, from ($1.20) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allakos is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allakos is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllakos has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Allakos' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.21% of the outstanding shares of Allakos have been sold short.Short Interest Ratio / Days to CoverAllakos has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allakos has recently increased by 1.03%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAllakos does not currently pay a dividend.Dividend GrowthAllakos does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.86 Percentage of Shares Shorted2.21% of the outstanding shares of Allakos have been sold short.Short Interest Ratio / Days to CoverAllakos has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allakos has recently increased by 1.03%, indicating that investor sentiment is decreasing. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 6 people have searched for ALLK on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Allakos insiders have not sold or bought any company stock.Percentage Held by Insiders16.12% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.64% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Allakos' insider trading history. Receive ALLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLK Stock News HeadlinesAllakos' (ALLK) Market Outperform Rating Reaffirmed at JMP SecuritiesSeptember 26, 2024 | americanbankingnews.comAllakos’s AK006 Poised for Strategic Advantage in CSU Market: A ‘Buy’ RecommendationSeptember 26, 2024 | markets.businessinsider.comWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.October 6, 2024 | Porter & Company (Ad)Allakos Inc. (ALLK) stock historical prices & data – Yahoo FinanceAugust 11, 2024 | au.finance.yahoo.comMaintaining Hold on Allakos: Weighing AK006 Promise Against Clinical SetbacksAugust 9, 2024 | markets.businessinsider.comHold Rating on Allakos Amid Uncertainty Over AK006’s Clinical Efficacy and Financial HealthAugust 8, 2024 | markets.businessinsider.comAllakos Provides Business Update and Reports Second Quarter 2024 Financial ResultsAugust 7, 2024 | globenewswire.comCan Allakos (NASDAQ:ALLK) Afford To Invest In Growth?July 23, 2024 | finance.yahoo.comSee More Headlines ALLK Stock Analysis - Frequently Asked Questions How have ALLK shares performed this year? Allakos' stock was trading at $2.73 at the beginning of 2024. Since then, ALLK stock has decreased by 74.7% and is now trading at $0.69. View the best growth stocks for 2024 here. How were Allakos' earnings last quarter? Allakos Inc. (NASDAQ:ALLK) issued its earnings results on Wednesday, August, 7th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.02. When did Allakos IPO? Allakos (ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager. How do I buy shares of Allakos? Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Allakos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE) and Eastman Chemical (EMN). Company Calendar Last Earnings8/07/2024Today10/06/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALLK CUSIPN/A CIK1564824 Webwww.allakos.com Phone(650) 597-5002FaxN/AEmployees131Year FoundedN/APrice Target and Rating Average Stock Price Target$1.67 High Stock Price Target$3.00 Low Stock Price Target$1.00 Potential Upside/Downside+141.5%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-185,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-123.58% Return on Assets-82.95% Debt Debt-to-Equity RatioN/A Current Ratio3.57 Quick Ratio3.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.93 per share Price / Book0.36Miscellaneous Outstanding Shares88,544,000Free Float74,271,000Market Cap$61.10 million OptionableOptionable Beta1.16 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:ALLK) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersHow much money are you leaving on the table from the stocks you already own?Charles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash...Unstoppable Prosperity | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allakos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.